A randomised phase III trial of high dose palliative radiotherapy (HDPRT) versus concurrent chemotherapy and HDPRT (C-HDPRT) in patients with good performance status, locally advanced/small volume metastatic NSCLC not suitable for radical chemo-radiotherapy.

The purpose of this study is to investigate whether adding chemotherapy to a short (less than six weeks) course of radiotherapy results in a greater improvement in symptoms and overall wellbeing (quality of life) compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC) who cannot be treated with surgery or a long (six weeks or longer) course of radiotherapy and chemotherapy.

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Participating Centres

Final Accrual


Current Accrual

Trial Chairperson

Associate Professor Margot Lehman, Princess Alexandra Hospital, QLD

Clinical Trial Registration

Related Post

February 28, 2022

Cancer trial participant hoping to help

The RAVES trial treating prostate cancer Participating in a

June 15, 2021

Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery

Ductal carcinoma in situ (DCIS) of the breast is

Skip to toolbar